Piribedil--an oral dopamine agonist for treatment of Parkinson's disease
Sweet, R.D.; Wasterlain, C.; McDowell, F.H.
Transactions of the American Neurological Association 99: 258-260
1974
ISSN/ISBN: 0065-9479 PMID: 4463553 Document Number: 71775
Document emailed within 1 workday
Related Documents
Jenner, P. 2005: A novel dopamine agonist for the transdermal treatment of Parkinson's disease Neurology 65(2 Suppl 1): S3-S5Molho, E.S.; Factor, S.A.; Weiner, W.J.; Sanchez-Ramos, J.R.; Singer, C.; Shulman, L.; Brown, D.; Sheldon, C. 1995: The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson's disease Journal of Neural Transmission. Supplementum 45: 225-230
Gekht, A.B. 2004: Treatment of Parkinson's disease: use of piribedil Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova 104(1): 54-56
2002: Dopamine agonist is effective in Parkinson disease not only against tremor. Depression is also improved MMW Fortschritte der Medizin Suppl. 2: 88
Bode, M. 2009: Dopamine agonist therapy in early Parkinson's disease. a survey of a Cochrane review Ugeskrift for Laeger 171(41): 2996-2999
Levin, O.S.; Nesterova, O.S.; Otcheskaia, O.V.; Zhuravleva, E.I.; Artemova, I.I.; Khozova, A.A.; Ismailov, A.M.; Lisenker, L.N.; Vdovichenko, T.V.; Rotor, L.D.; Ganzula, P.A.; Ivanov, A.K.; Boĭko, A.N. 2009: Influence of dopamine agonist pramipexole (mirapex) on tremor, cognitive and affective impairment in patients with Parkinson's disease Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova 109(8): 36-41
Suwantamee, J.; Nidhinandana, S.; Srisuwananukorn, S.; Laptikultham, S.; Pisarnpong, A.; Chankrachang, S.; Bundhukul, A. 2004: Efficacy and safety of piribedil in early combination with L-dopa in the treatment of Parkinson's disease: a 6-month open study Journal of the Medical Association of Thailand 87(11): 1293-1300
Ziégler, M.; Rondot, P. 1999: Action of piribedil in Parkinson disease. Multicenter study Presse Medicale 28(26): 1414-1418
Gekht, A.B. 2002: Use of dopamine agonists in the treatment of Parkinson's disease Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova 102(9): 54-58
Olanow, C.Warren. 2002: The role of dopamine agonists in the treatment of early Parkinson's disease Neurology 58(4 Suppl 1): S33-S41
Streifler, M.; Vardi, Y.; Kesten, M.; Oberman, Z.; Herzberg, M. 1972: Urinary excretion of dopamine and homovanillic acid during L-dopa treatment of Parkinson's disease Israel Journal of Medical Sciences 81(5): 597-601
Buscaino, G.A.; Sori, A.; Campanella, G. 1972: Study of dopamine and noradrenaline in the brains of three patients with Parkinson's disease who died in the course of treatment with L-dopa Revue Neurologique (Paris) 127(2): 301-302
Fuchs, G. 1997: Parkinson disease--problems in long-term treatment. Dopamine agonists optimize L-dopa therapy Fortschritte der Medizin 115(5): 43-45
Krivonos, O.V.; Fedorova, N.V.; Chigir', I.P. 2004: A comparative study of efficacy of dopamine receptors agonists and catechol-O-methyltransferase in the treatment of late stages of Parkinson's disease Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova 104(1): 24-30
Babeau, P.; Pras, P.; Serizet, A. 1980: Piribedil, dopaminergic agonist and the cerebral neurovascular syndrom of the aging man La Semaine des Hopitaux: Organe Fonde Par l'Association d'Enseignement Medical des Hopitaux de Paris 56(3-4): 188-192
Swart, P.J.; De Zeeuw, R.A. 1992: Extensive gastrointestinal metabolic conversion limits the oral bioavailability of the dopamine D2 agonist N-0923 in freely moving rats Die Pharmazie 47(8): 613-615
Malmberg; Mikaels; Mohell, N. 1998: Agonist and inverse agonist activity at the dopamine D3 receptor measured by guanosine 5'--gamma-thio-triphosphate--35S- binding Journal of Pharmacology and Experimental Therapeutics 285(1): 119-126
Ziegler, M.; Georgiadis, G.; Elghozi, J.L. 1984: Acute hypotensive effect of a central dopaminergic agonist, piribedil, administered intravenously in the normotensive human Archives des Maladies du Coeur et des Vaisseaux 77(11): 1186-1190
Ceccherini-Nelli, A.; Guazzelli, M. 1994: Treatment of refractory OCD with the dopamine agonist bromocriptine Journal of Clinical Psychiatry 55(9): 415-416
Eijsbouts, A.; van den Hoogen, F.; Laan, R.F.; Hermus, R.M.; Sweep, F.C.; van de Putte, L. 1999: Treatment of rheumatoid arthritis with the dopamine agonist quinagolide Journal of Rheumatology 26(10): 2284-2285